186 related articles for article (PubMed ID: 10406497)
21. Association between Asymmetric Dimethylarginine and Pentosidine in Dialysis Effluent of Peritoneal Dialysis Patients -A possible intraperitoneal crosstalk between asymmetric dimethylarginine and advanced glycation end products in peritoneal dialysis patients.
Ishida M; Kakuta T; Miyakogawa T; Tatsumi R; Matsumoto C; Fukagawa M
Tokai J Exp Clin Med; 2016 Jun; 41(2):97-100. PubMed ID: 27345001
[TBL] [Abstract][Full Text] [Related]
22. Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality.
de Waart DR; Zweers MM; Struijk DG; Krediet RT
Perit Dial Int; 2001; 21(3):269-74. PubMed ID: 11475342
[TBL] [Abstract][Full Text] [Related]
23. Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis.
Lamb E; Cattell WR; Dawnay A
Clin Sci (Lond); 1993 Jun; 84(6):619-26. PubMed ID: 8334808
[TBL] [Abstract][Full Text] [Related]
24. Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.
Ahmad M; Shah H; Pliakogiannis T; Oreopoulos DG
Int Urol Nephrol; 2007; 39(1):299-312. PubMed ID: 17004033
[TBL] [Abstract][Full Text] [Related]
25. Intraperitoneal infusion of glucose-based dialysate in the rat--an animal model for the study of peritoneal advanced glycation end-products formation and effect on peritoneal transport.
Zeltzer E; Klein O; Rashid G; Katz D; Korzets Z; Bernheim J
Perit Dial Int; 2000; 20(6):656-61. PubMed ID: 11216555
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress.
Lapolla A; Reitano R; Seraglia R; Sartore G; Ragazzi E; Traldi P
Mol Nutr Food Res; 2005 Jul; 49(7):685-90. PubMed ID: 15926142
[TBL] [Abstract][Full Text] [Related]
27. Kinetic analysis of furosine and pentosidine in CAPD patients.
Kumano K; Yokota S; Sakai T; Kobayashi N; Yoshida A; Yoshihara T; Shibata K; Izumi G; Wang H
Adv Perit Dial; 1997; 13():53-7. PubMed ID: 9360651
[TBL] [Abstract][Full Text] [Related]
28. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
Parikova A; Zweers MM; Struijk DG; Krediet RT
Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
[TBL] [Abstract][Full Text] [Related]
29. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study.
Rodríguez-Carmona A; Pérez Fontán M; García López E; García Falcón T; Díaz Cambre H
Perit Dial Int; 2007; 27(3):260-6. PubMed ID: 17468473
[TBL] [Abstract][Full Text] [Related]
30. Predicting the Peritoneal Absorption of Icodextrin in Rats and Humans Including the Effect of α-Amylase Activity in Dialysate.
Akonur A; Holmes CJ; Leypoldt JK
Perit Dial Int; 2015; 35(3):288-96. PubMed ID: 24584610
[TBL] [Abstract][Full Text] [Related]
31. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure.
Wiggins KJ; Rumpsfeld M; Blizzard S; Johnson DW
Nephrology (Carlton); 2005 Feb; 10(1):33-6. PubMed ID: 15705179
[TBL] [Abstract][Full Text] [Related]
32. In vitro formation of advanced glycation end products in peritoneal dialysis fluid.
Lamb EJ; Cattell WR; Dawnay AB
Kidney Int; 1995 Jun; 47(6):1768-74. PubMed ID: 7643548
[TBL] [Abstract][Full Text] [Related]
33. Glycated adducts induce mesothelial cell transdifferentiation: role of glucose and icodextrin dialysis solutions.
Conti G; Amore A; Cirina P; Peruzzi L; Balegno S; Coppo R
J Nephrol; 2008; 21(3):426-37. PubMed ID: 18587733
[TBL] [Abstract][Full Text] [Related]
34. Decreased in vitro formation of AGEs with extraneal solution compared to dextrose-containing peritoneal dialysis solutions.
Barre DE; Chen C; Cooker L; Moberly JB
Adv Perit Dial; 1999; 15():12-6. PubMed ID: 10682064
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.
Zweers MM; Struijk DG; Smit W; Krediet RT
J Lab Clin Med; 2001 Feb; 137(2):125-32. PubMed ID: 11174469
[TBL] [Abstract][Full Text] [Related]
36. [Effect of a dialysis solution with icodextrin on ultrafiltration and selected metabolic parameters in patients treated with peritoneal dialysis].
Opatrná S; Racek J; Stehlík P; Senft V; Sefrna F; Topolcan O; Opatrný K
Cas Lek Cesk; 2002 May; 141(9):281-5. PubMed ID: 12061197
[TBL] [Abstract][Full Text] [Related]
37. Strategies to reduce glucose exposure in peritoneal dialysis patients.
Holmes CJ; Shockley TR
Perit Dial Int; 2000; 20 Suppl 2():S37-41. PubMed ID: 10911641
[TBL] [Abstract][Full Text] [Related]
38. Icodextrin: a review of its use in peritoneal dialysis.
Frampton JE; Plosker GL
Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
[TBL] [Abstract][Full Text] [Related]
39. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid.
Anderstam B; García-López E; Heimbürger O; Lindholm B
Perit Dial Int; 2003; 23(2):146-50. PubMed ID: 12713081
[TBL] [Abstract][Full Text] [Related]
40. [Clinical experience with icodextrin. Multicenter study].
Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Remón C; Fernández-Ruiz EJ; Pérez-Bañasco V; Benítez M; Martínez-Benavides E; Martínez-González JM; Torán D; Tejuca F; Páez C; del Pino MD
Nefrologia; 2001; 21(6):574-80. PubMed ID: 11881427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
